Product Description
Delavirdine is a nonnucleoside reverse transcriptase inhibitor used in combination with other agents in the therapy of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Delavirdine is associated with a low rate of transient serum aminotransferase elevations during therapy and is a rare cause of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Delavirdine)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Chile | Colombia | New Zealand | Peru | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/20/2025 |
News Article |
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal |
|
10/06/2025 |
News Article |
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® |
|
08/18/2025 |
News Article |
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million |
|
05/02/2025 |
News Article |
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress |